PM
SRPT icon

Parametrica Management’s Sarepta Therapeutics SRPT Stock Holding History

Parametrica Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,774
Closed -$276K – 172
2021
Q1 		$276K Buy
3,774
+1,539
+69% +$142K 0.13% 116
2020
Q4 		$381K Buy
+2,235
New +$331K 0.24% 86

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Parametrica Management's SRPT Position: Q2 2021 in Review

Parametrica Management sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 3,774 shares — an estimated $276K sold.

Parametrica Management first reported a position in SRPT in Q4 2020 and held it in 2 quarters. The position peaked at $381K in Q4 2020. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • Parametrica Management reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Parametrica Management sold 3,774 Sarepta Therapeutics shares in Q2 2021, an estimated $276K.
  • Parametrica Management first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 2 quarters.
  • Parametrica Management's Sarepta Therapeutics position peaked at $381K in Q4 2020.
  • 330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Parametrica Management's 13F filing for Q2 2021, filed 13 Aug 2021.